What is the Alzheimer’s Disease Diagnostics Market forecast for 2035?

Revenue is projected to reach USD 4.05 Billion by 2035.

What is the CAGR of the Alzheimer’s Disease Diagnostics Market from 2026 to 2035?

The market is forecast to grow at a 14.6% CAGR over 2026–2035.

Which diagnostic method dominates the market?

PET imaging leads with USD 0.45 Billion, or about 38% of 2026 revenue.

Which diagnostic method is growing fastest?

Blood based biomarker tests grow fastest at 20.6% CAGR through 2035.

Which region dominates the market?

North America leads with about 45% of 2026 revenue, or USD 0.54 Billion.

Which region is expanding fastest?

Asia-Pacific is fastest at 18.4% CAGR, reaching USD 1.14 Billion by 2035.

Which country has the largest market?

The U.S. is largest, projected to reach USD 1.50 Billion by 2035.

Who are the key players?

Roche, Danaher through Beckman Coulter, H.U. Group through Fujirebio, Lantheus, Quest Diagnostics, Labcorp, Quanterix and C2N Diagnostics are the eight profiled companies.

What drives market growth?

Anti amyloid therapy selection and FDA cleared blood tests add up to 4.7 percentage points of CAGR impact in our matrix.

What restrains the market?

Reimbursement gaps reduce CAGR by about 1.8 percentage points, and confirmatory testing adds a further 1.1 point drag.

What opportunities exist for vendors?

Primary care rules out testing and emerging markets help add USD 2.86 Billion of revenue between 2026 and 2035.

How is technology reshaping diagnosis?

Plasma pTau217 assays raise blood test revenue from USD 0.36 Billion in 2026 to USD 1.95 Billion by 2035.

How does regulation influence the market?

The FDA cleared the first Alzheimer’s blood test in May 2025. In the cited study, 91.7% of positive results and 97.3% of negative results agreed with PET or cerebrospinal fluid findings. FDA clearance does not itself guarantee reimbursement

What is the market outlook for India?

India is the fastest growing country, expanding at 23.5% CAGR to USD 0.20 Billion by 2035.

Alzheimer’s Disease Diagnostics Market Size & Share: USD 4.05 Bn 2035

Name: Alzheimer’s Disease Diagnostics Market Size & Share: USD 4.05 Bn 2035
Creator: Next Move Strategy Consulting
Published: 2026-11-03T00:00:00+00:00
License: https://www.nextmsc.com/privacy-policy

Research Methodology

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Methodology Nmsc Updated

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

Porters 5 Updated 2

SWOT Analysis

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

What Is the Alzheimer’s Disease Diagnostics Market Size?

The Alzheimer’s Disease Diagnostics Market was valued at USD 1.02 Billion in 2025 and is estimated at USD 1.19 Billion in 2026. It is forecast to reach USD 4.05 Billion by 2035, growing at a 14.6% CAGR from 2026 to 2035. North America leads with about 45% share, while PET imaging holds roughly 38% of 2026 revenue.

Three factors shape the market outlook: regulated blood-based tests, amyloid and tau PET radiotracers, and cerebrospinal fluid biomarker assays .The key takeaways below summarize leadership by segment and geography for the forecast window.

Alzheimer’s disease diagnostics Market Analysis and Forecast Revenue Forecast

Values in USD Billion

2025 $1.02 Billion

2025

2026 $1.19 Billion

2026

2027 $1.36 Billion

2027

2028 $1.56 Billion

2028

2029 $1.79 Billion

2029

2030 $2.05 Billion

2030

2031 $2.35 Billion

2031

2032 $2.70 Billion

2032

2033 $3.09 Billion

2033

2034 $3.54 Billion

2034

2035 $4.05 Billion

2035

Key Takeaways

By Diagnostic Method: PET imaging held the largest share, expanding from USD 0.40 Billion in 2025 to USD 1.27 Billion by 2035; Blood-based biomarker tests are the fastest-growing at 20.6% CAGR from 2026–2035.

By Biomarker Target: Amyloid pathology held the largest share, expanding from USD 0.58 Billion in 2025 to USD 1.70 Billion by 2035; Tau pathology is the fastest-growing at 19.1% CAGR from 2026–2035.

By End User: Reference and diagnostic laboratories held the largest share, with revenue projected to increase from USD 0.33 Billion in 2025 to USD 1.62 Billion by 2035. The segment is also projected to be the fastest-growing, at a 16.8% CAGR from 2026 to 2035.

Dominant Region: North America accounted for about 45.4% of 2026 revenue, rising from USD 0.47 Billion in 2025 to USD 1.65 Billion by 2035.

Fastest-Growing Region: Asia-Pacific is expanding at 18.4% CAGR from 2026–2035, reaching USD 1.14 Billion by 2035.

Dominant Country: The U.S. is the largest national market, growing from USD 0.43 Billion in 2025 to USD 1.50 Billion by 2035.

Fastest-Growing Country: India leads growth at 23.5% CAGR from 2026–2035, reaching USD 0.20 Billion by 2035.

Our findings suggest that the Alzheimer’s Disease Diagnostics Market adds an incremental revenue opportunity of USD 2.86 Billion between 2026 and 2035, which positions diagnostic infrastructure as an attractive investment theme.

According to NMSC analysis, the share of revenue from blood tests rises from 30% in 2026 to 48% in 2035 as screening workflows shift away from lumbar puncture.

Ecosystem Analysis of the Alzheimer’s Disease Diagnostics Market

The infographic outlines the Ecosystem Analysis of the Alzheimer’s Disease Diagnostics Market, highlighting key stakeholders such as diagnostic companies, healthcare providers, research institutions, and end users. It emphasizes how biomarker discovery, diagnostic innovation, regulatory support, and strategic partnerships contribute to early detection, improved diagnostic accuracy, wider access to testing, and long-term market growth

What Does the Alzheimer’s Disease Diagnostics Market Encompass?

This Alzheimer’s Disease Diagnostics market report covers in vitro and imaging products that help clinicians confirm or exclude Alzheimer’s pathology in symptomatic adults. Scope includes plasma and cerebrospinal fluid biomarker assays for amyloid beta, phosphorylated tau, neurofilament light and glial fibrillary acidic protein, amyloid and tau PET radiotracers, and genetic risk testing such as APOE genotyping. Digital cognitive screening, treatments and caregiver services fall outside the revenue definition.
We observed that regulation now defines the structure of the field. In May 2025, the U.S. FDA cleared the first blood test to aid diagnosis, and additional clearances followed in 2026. Laboratory developed tests still account for a large share of volume, while instrument makers push standardized kits onto installed immunoassay platforms. Reimbursement, guideline updates and therapy labelling continue to widen the eligible patient pool for neurological biomarkers.

Key Emerging Trends

Our assessment indicates that four shifts are redefining how Alzheimer’s evaluation is delivered, priced and reimbursed across care settings.

How Are Blood Biomarker Tests Reshaping Diagnostic Pathways?

Plasma testing is moving from research use into regulated clinical practice. The FDA cleared the Lumipulse pTau217 and beta-amyloid 1-42 plasma ratio in May 2025 after a study of 499 cognitively impaired adults, where 91.7% of positive results and 97.3% of negative results matched PET or cerebrospinal fluid findings. Later clearances for Elecsys pTau217 and PrecivityAD2 broaden choice. Clinicians gain a less invasive first step that lowers PET and lumbar puncture referrals.

Why Are Multi Biomarker Panels Gaining Traction?

Single marker tests leave an intermediate zone that forces follow up testing. Quanterix reports that its LucentAD Complete panel combines p-tau217, amyloid ratios, neurofilament light, and GFAP to support Alzheimer’s disease assessment. The company also reported a CMS-approved reimbursement amount of USD 897 in November 2025; this should not be interpreted as universal payer coverage. Quest Diagnostics announced an AD-Detect offering in August 2026 and reported a 10% indeterminate rate for the panel. Laboratories therefore compete on conclusive answers per sample rather than price alone.

How Is Laboratory Automation Extending Testing Beyond Specialist Centers?

Assays that run on existing high throughput analyzers lower the barrier for community laboratories. Fujirebio designed its plasma ratio for the Lumi pulse platform widely installed across U.S. labs, Beckman Coulter built its Access p-Tau217 assay for the DxI 9000 analyzer, and Roche runs Elecsys assays on its widely installed laboratory analyzers. We found that this standardization shortens turnaround and supports primary care triage, particularly rule out testing before specialist referral.

How Is PET Imaging Adapting to Therapy Selection?

Amyloid PET is an established method for confirming amyloid pathology and assessing eligibility for anti-amyloid treatment. Validated cerebrospinal fluid and blood-based biomarkers may also contribute to diagnostic pathways, depending on the test indication and applicable clinical guidance. Lantheus acquired Life Molecular Imaging in July 2025, adding Neuraceq, whose labeling was updated in 2025 to cover patient selection for amyloid targeting therapies and quantitative analysis. Tracer makers are adding manufacturing sites and tau agents such as MK-6240 are advancing toward approval, which keeps imaging relevant even as blood tests absorb routine volumes.

Market Drivers & Dynamics

Interactive Dataset


Regulatory clearance of blood tests	driver	+2.8%	U.S., Europe, Japan	2026–2030
Anti amyloid therapy patient selection	driver	+2.4%	North America, Europe	2026–2032
Ageing population and rising prevalence	driver	+1.9%	Global	2026–2035
Multi biomarker and automated platforms	driver	+1.2%	Global	2026–2031
Reimbursement and coverage gaps	restraint	−1.8%	Global, notably Europe and APAC	2026–2029
Indeterminate and confirmatory testing burden	restraint	−1.1%	Global	2026–2030
PET tracer cost and scanner access	restraint	−0.9%	Emerging markets	2026–2031

Source: Next Move Strategy Consulting

Growth Drivers

What Is the Primary Growth Driver?

The leading driver is demand for accurate patient selection as anti-amyloid antibodies reach clinics. The Alzheimer’s Association estimates that 7.4 million Americans aged 65 and older live with Alzheimer’s dementia in 2026. The World Health Organization estimated that more than 57 million people worldwide were living with dementia in 2021. Patients being considered for anti-amyloid therapies generally require confirmation of amyloid pathology. This makes appropriate biomarker testing an important part of treatment eligibility assessment.

How Is Regulatory and Payer Progress Driving Market Growth?

Our analysis shows that clearances and coverage decisions convert scientific validity into purchasable volume. C2N Diagnostics received FDA clearance for PrecivityAD2 in August 2026 for its indicated patient population, including adults aged 40 and older. Roche Diagnostics also received FDA clearance for Elecsys pTau217, developed in collaboration with Eli Lilly. Anthem revised its medical policy for Alzheimer’s biochemical marker testing effective July 1, 2026; coverage depends on the policy’s clinical criteria. Each decision lowers the administrative cost of ordering and invites wider primary care adoption.

Growth Inhibitors

What Is Restraining the Market?

The main restraint is uneven reimbursement combined with residual diagnostic uncertainty. The FDA reported that fewer than 20% of patients in the study of the first cleared plasma ratio received indeterminate results. The test’s results must be interpreted in accordance with its cleared indication and clinical context, and FDA clearance should not be interpreted as eliminating the risk of incorrect results. Confirmatory PET or spinal fluid testing therefore persists, and payers in many countries still limit coverage to specialist settings.

Segmentation Analysis

2025 (USD Billion)

2035 (USD Billion)

Blood-based biomarker tests 2025: $0.28 Billion | 2035: $1.95 Billion

Blood-based

CSF biomarker tests 2025: $0.27 Billion | 2035: $0.62 Billion

CSF biomarke

PET imaging 2025: $0.40 Billion | 2035: $1.27 Billion

PET imaging

Genetic testing 2025: $0.07 Billion | 2035: $0.21 Billion

Genetic test


Blood-based biomarker tests	$0.28 Billion	$1.95 Billion	20.6%
CSF biomarker tests	$0.27 Billion	$0.62 Billion	8.8%
PET imaging	$0.40 Billion	$1.27 Billion	12.2%
Genetic testing	$0.07 Billion	$0.21 Billion	9.9%

Which Diagnostic Method Leads the Market and Which Grows Fastest?

PET imaging is the largest method in 2026 at USD 0.45 Billion, supported by established radiotracers and their role in therapy eligibility. Blood tests are the fastest growing at 20.6% because clearances, instrument compatibility and lower cost per patient widen access. CSF testing grows more slowly at 8.8%. Genetic testing stays small at 9.9%, although falling next generation sequencing costs support steady demand for APOE and familial panels.

2025 (USD Billion)

2035 (USD Billion)

Amyloid path

Tau patholog

Neurodegener

Genetic risk

Segment Item	2025 (USD Billion)	2035 (USD Billion)	CAGR
Amyloid pathology	$10.0 USD Billion	$40.0 USD Billion	23.0%
Tau pathology	$17.1 USD Billion	$51.1 USD Billion	25.0%
Neurodegeneration and neuroinflammation	$24.2 USD Billion	$62.2 USD Billion	11.0%
Genetic risk	$31.3 USD Billion	$73.3 USD Billion	17.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Biomarker Target.

Unlock Full Data

2025 (USD Billion)

2035 (USD Billion)

Hospitals an

Reference an

Imaging cent

Pharmaceutic

Segment Item	2025 (USD Billion)	2035 (USD Billion)	CAGR
Hospitals and memory clinics	$10.0 USD Billion	$40.0 USD Billion	26.0%
Reference and diagnostic laboratories	$17.1 USD Billion	$51.1 USD Billion	16.0%
Imaging centers	$24.2 USD Billion	$62.2 USD Billion	18.0%
Pharmaceutical and research institutions	$31.3 USD Billion	$73.3 USD Billion	8.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By End User.

Unlock Full Data

2025 (USD Billion)

2035 (USD Billion)

North Americ

U.S.

Canada

Mexico

Europe

Segment Item	2025 (USD Billion)	2035 (USD Billion)	CAGR
North America	$10.0 USD Billion	$40.0 USD Billion	10.0%
U.S.	$17.1 USD Billion	$51.1 USD Billion	8.0%
Canada	$24.2 USD Billion	$62.2 USD Billion	18.0%
Mexico	$31.3 USD Billion	$73.3 USD Billion	8.0%
Europe	$38.4 USD Billion	$84.4 USD Billion	15.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Region.

Unlock Full Data

Growth Opportunities

We observed three concrete openings that extend revenue beyond specialist memory clinics over the forecast period.

Can Primary Care Rule Out Testing Unlock New Volume?

Blood tests that confidently exclude amyloid pathology let general practitioners avoid unnecessary specialist referrals, so laboratories and kit makers selling to primary care networks gain a large untapped test base. Beneficiaries include national reference laboratories and platform vendors whose analyzers already sit in community hospitals, and the opportunity grows as guidelines endorse dual cutoff interpretation.

Will Emerging Markets Create the Next Wave of Demand?

Countries across Asia-Pacific and the Middle East are building memory clinic capacity while PET access stays limited, which favors affordable plasma assays and local laboratory partnerships for regional distributors and instrument suppliers. Beneficiaries include assay makers with CE marked or locally registered kits, and the largest gains arise in China, India, Japan and Saudi Arabia where governments fund dementia programs.

How Can Pharmaceutical Partnerships Create Recurring Revenue?

Drug developers need screening, enrolment and treatment response monitoring across large trials. Diagnostic companies offering validated plasma and tau PET assays can secure multiyear service contracts with sponsors and central laboratories. Beneficiaries include specialist assay companies and PET tracer suppliers, because trial screening failure rates are high and each enrolled patient generates repeated testing across the treatment period.

Regional Outlook

2025 (USD Billion)

2035 (USD Billion)

North Americ

Europe

Asia-Pacific

Middle East

Latin Americ

Region	2025 (USD Billion)	2035 (USD Billion)	CAGR (%)
North America	$10.0 USD Billion	$40.0 USD Billion	9.0%
Europe	$17.1 USD Billion	$51.1 USD Billion	27.0%
Asia-Pacific	$24.2 USD Billion	$62.2 USD Billion	25.0%
Middle East & Africa	$31.3 USD Billion	$73.3 USD Billion	23.0%
Latin America	$38.4 USD Billion	$84.4 USD Billion	12.0%

Regional data is locked

Unlock complete regional numbers for this market.

Unlock Full Data

North America Alzheimer’s Disease Diagnostics Market

2025 Size

$0.47 Billion

CAGR

13.2%

The North America Alzheimer's Disease Diagnostics Market generated USD 0.54 Billion in 2026, representing approximately 45.4% of global revenue. The region has the earliest FDA cleared blood tests, established Medicare coverage for amyloid PET in selected settings and a dense network of national laboratories. Therapy eligibility drives demand for confirmatory testing. We observed that commercial payers such as Anthem are now covering blood biomarker tests, which should keep growth near 13.2% through 2035 as primary care adoption begins.

Primary Driver: FDA clearances and therapy driven testing

Key National Markets

U.S. Alzheimer’s Disease Diagnostics Market

For U.S., we project revenue of USD 0.43 Billion in 2025 and USD 1.50 Billion by 2035, a 13.2% CAGR for 2026–2035.

Canada Alzheimer’s Disease Diagnostics Market

Our model sizes Canada at USD 0.03 Billion in 2025 and USD 0.12 Billion in 2035, equal to a 13.0% CAGR from 2026 to 2035.

Europe Alzheimer’s Disease Diagnostics Market

2025 Size

$0.27 Billion

CAGR

14.1%

The Europe Alzheimer's Disease Diagnostics Market reached USD 0.31 Billion in 2026 and is projected to grow at a 14.1% CAGR from 2026 to 2035. CE marking under the IVDR has become the main gate, and Beckman Coulter secured it for Access p-Tau217 in 2026. Health technology assessment bodies move cautiously on reimbursement, so adoption centers on national memory clinic networks. Germany, the UK and France hold the largest installed base of immunoassay analyzers and PET scanners.

Primary Driver: IVDR approvals and national dementia plans

Key National Markets

UK Alzheimer’s Disease Diagnostics Market

We estimate UK revenue at USD 0.05 Billion in 2025, growing to USD 0.19 Billion by 2035 with a 13.7% CAGR over 2026–2035.

Germany Alzheimer’s Disease Diagnostics Market

By 2035 we expect Germany to generate USD 0.26 Billion, up from USD 0.07 Billion in 2025, for a 14.0% CAGR from 2026.

France Alzheimer’s Disease Diagnostics Market

For France, we project revenue of USD 0.04 Billion in 2025 and USD 0.16 Billion by 2035, a 13.8% CAGR for 2026–2035.

Asia-Pacific Alzheimer’s Disease Diagnostics Market

2025 Size

$0.21 Billion

CAGR

18.4%

The Asia-Pacific Alzheimer's Disease Diagnostics Market is the fastest-growing region at an 18.4% CAGR, rising from USD 0.25 Billion in 2026 to USD 1.14 Billion by 2035. Japan, China and South Korea combine rapid population ageing with strong laboratory automation. Our assessment indicates that governments are funding dementia screening programs, while local manufacturers file regional approvals for plasma tests. Limited PET capacity outside major cities favors blood-based workflows.

Primary Driver: Large ageing populations and new memory clinics

Key National Markets

China Alzheimer’s Disease Diagnostics Market

Our model sizes China at USD 0.05 Billion in 2025 and USD 0.34 Billion in 2035, equal to a 21.3% CAGR from 2026 to 2035.

India Alzheimer’s Disease Diagnostics Market

We estimate India revenue at USD 0.02 Billion in 2025, growing to USD 0.20 Billion by 2035 with a 23.5% CAGR over 2026–2035.

Japan Alzheimer’s Disease Diagnostics Market

By 2035 we expect Japan to generate USD 0.27 Billion, up from USD 0.07 Billion in 2025, for a 14.5% CAGR from 2026.

South Korea Alzheimer’s Disease Diagnostics Market

For South Korea, we project revenue of USD 0.02 Billion in 2025 and USD 0.12 Billion by 2035, a 16.7% CAGR for 2026–2035.

Australia Alzheimer’s Disease Diagnostics Market

Our model sizes Australia at USD 0.02 Billion in 2025 and USD 0.07 Billion in 2035, equal to a 14.9% CAGR from 2026 to 2035.

Middle East & Africa Alzheimer’s Disease Diagnostics Market

2025 Size

$0.04 Billion

CAGR

12.1%

The Middle East & Africa Alzheimer's Disease Diagnostics Market remains at a small base of USD 0.05 Billion in 2026 but is projected to expand at a 12.1% CAGR through 2035. Gulf states invest in specialist neurology centers and import validated assays, whereas Sub-Saharan markets rely on limited referral laboratories. Cost remains the main barrier, so growth depends on public procurement, partnerships with international laboratory networks and regional distribution of automated immunoassay platforms.

Primary Driver: Specialist center builds out

Key National Markets

Saudi Arabia Alzheimer’s Disease Diagnostics Market

By 2035 we expect Saudi Arabia to generate USD 0.04 Billion, up from USD 0.01 Billion in 2025, for a 16.7% CAGR from 2026.

UAE Alzheimer’s Disease Diagnostics Market

We estimate UAE revenue at USD 0.01 Billion in 2025, growing to USD 0.03 Billion by 2035 with a 13.0% CAGR over 2026–2035.

South Africa Alzheimer’s Disease Diagnostics Market

For South Africa, we project revenue of USD 0.01 Billion in 2025 and USD 0.03 Billion by 2035, a 13.0% CAGR for 2026–2035.

Latin America Alzheimer’s Disease Diagnostics Market

2025 Size

$0.03 Billion

CAGR

10.7%

The Latin America Alzheimer's Disease Diagnostics Market reached USD 0.04 Billion in 2026 and is forecast to grow at a 10.7% CAGR over 2026–2035. Brazil and Argentina host most private neurology practice and imaging capacity, while public systems rarely reimburse biomarker testing. We found that large private laboratory chains are introducing plasma panels to differentiate their neurology menus. Currency volatility and import dependence on reagents continue to temper investment decisions.

Primary Driver: Private laboratory expansion

Key National Markets

Brazil Alzheimer’s Disease Diagnostics Market

Our model sizes Brazil at USD 0.02 Billion in 2025 and USD 0.06 Billion in 2035, equal to a 13.0% CAGR from 2026 to 2035.

Argentina Alzheimer’s Disease Diagnostics Market

We estimate Argentina revenue at USD 0.01 Billion in 2025, growing to USD 0.02 Billion by 2035 with an 8.0% CAGR over 2026–2035.

Strategic Framework of the Alzheimer’s Disease Diagnostics Market

The infographic highlights the Strategic Framework Impacting the Alzheimer’s Disease Diagnostics Market, focusing on innovation and technology, regulatory and policy support, collaboration and partnerships, and market access and awareness. It illustrates how advancements in biomarker and imaging technologies, improved diagnostic accuracy, streamlined approvals, and greater awareness of early detection support wider access to diagnostic solutions, better patient outcomes, and long-term market growth

Competitive Landscape

Our findings suggest that the Alzheimer’s diagnostics industry is consolidating around platform owners, national laboratories and radiotracer suppliers.

How Do Companies Compete in This Market?

Competition runs along three lines. Instrument makers such as Roche, Beckman Coulter and Fujirebio win by placing validated kits on analyzers laboratories already own. Laboratory networks including Quest Diagnostics and LabCorp compete on access, branding and physician education. Specialists such as C2N and Quanterix compete on analytical performance and proprietary algorithms, and regulatory clearance is a decisive advantage.

Which Company Archetypes Dominate?

Three archetypes dominate. Platform incumbents offer broad immunoassay menus and global service networks. Service laboratories offer branded tests with national physician reach. Specialist innovators bring mass spectrometry or ultra-sensitive immunoassay technology. Differentiation themes include indeterminate result rates, age range of cleared use, throughput per instrument and the strength of clinical evidence generated in real world cohorts.

How Are Companies Differentiating Through Innovation?

Innovation centers on narrowing the intermediate zone and widening clinical use. C2N obtained clearance from age 40, Quest introduced a multi biomarker panel with a 10% indeterminate rate, and Quanterix has submitted its multi marker test to the FDA. Vendors also pursue companion roles with drug developers and add pricing models that bundle reagents, instruments and software.

What Is the Level of M&A Activity?

Deal activity is selective rather than broad. Lantheus acquired Life Molecular Imaging in July 2025 to obtain Neuraceq, and Roche partnered with Eli Lilly on Elecsys pTau217 development. Laboratory networks sign supply and licensing agreements with assay makers. We expect geographic expansion through distributors in Asia-Pacific, and pricing strategies to shift toward bundled contracts as clinical volumes increase.

Key Market Players

NMSC’s analysis indicates that the following eight companies, ranked qualitatively by diagnostic scale and relevance, shape competition in this industry.

Roche Holding AG Danaher Corporation (Beckman Coulter Diagnostics) H.U. Group Holdings, Inc. (Fujirebio) Lantheus Holdings, Inc. Quest Diagnostics Incorporated Laboratory Corporation of America Holdings (Labcorp) Quanterix Corporation C2N Diagnostics, LLC

Latest Developments

We found that regulatory and reimbursement milestones dominated company activity in 2025 and 2026.

Date	Event
August 2026	The FDA cleared Roche Diagnostics’ Elecsys pTau217 blood test, developed in collaboration with Eli Lilly. Quest Diagnostics separately announced plans to offer the test through its AD-Detect portfolio.

Expert Insights

Maria C. Carrillo

Chief Science Officer and Medical Affairs Lead | Alzheimer’s Association

"“Each FDA clearance gives clinicians another validated option to work with when evaluating patients showing signs of cognitive impairment.”"

Analyst Interpretation

The statement highlights the expanding range of validated blood-based biomarkers available for Alzheimer’s disease assessment. As testing options develop, clinicians can incorporate these tools into diagnostic workflows alongside clinical evaluation and other established methods. This is supporting the evolution of the market toward more accessible biomarker testing and broader diagnostic options

Market Interpretation

Investment Opportunities

Where Are Capital Inflows Concentrated?

Capital flows toward assay development, laboratory build out and radiopharmaceutical acquisitions. Quanterix developed LucentAD Complete with funding from the Alzheimer’s Drug Discovery Foundation Diagnostics Accelerator, and Lantheus paid for Life Molecular Imaging to secure amyloid and tau imaging assets. Investors favor companies with regulatory clearances, reimbursement codes and recurring reagent revenue tied to installed instruments.

How Does Infrastructure Investment Shape Returns?

Returns depend on installed analyzers, PET manufacturing sites and laboratory capacity. Lantheus reports continued expansion of PET manufacturing sites to extend geographic access, while diagnostic makers target platforms already present in thousands of laboratories. Infrastructure that serves many biomarkers per instrument lowers cost per test and supports multi-year contracts with national laboratory networks.

What Are the ESG Considerations?

Access and equity are central. Older Black Americans are about twice as likely to have Alzheimer’s or other dementias as older White Americans, and about 200,000 Americans under 65 have younger onset disease. Blood tests reduce invasive procedures and travel burden, yet validated performance across diverse populations and fair reimbursement remain priorities for responsible investors.

Key Benefits for Stakeholders

How Does the Report Help Enterprise and Industry Leaders?

Executives at diagnostic, laboratory and imaging companies receive a segmented forecast from 2025 to 2035, regional and country sizing, and a view of competitive archetypes. These insights support platform selection, regulatory prioritization and partnership decisions, particularly on whether to build laboratory developed tests or pursue cleared kits, and where to expand geographically.

How Does the Report Help Investors and Financial Analysts?

Investors obtain a reconciled market model showing a USD 1.19 Billion base in 2026, a 14.6% CAGR and a USD 2.86 Billion incremental opportunity. Segment growth rates highlight where returns concentrate, including blood tests and tau markers, while the restraint analysis clarifies reimbursement and confirmatory testing risks that affect valuation assumptions.

How Does the Report Help Technology Vendors and Clinical Teams?

Vendors and clinical leaders gain evidence on where automation, multi biomarker algorithms and tau imaging create advantages. The analysis outlines adoption barriers in primary care, differences between countries and the role of guidelines, helping product teams and memory clinic leaders prioritize indications, age ranges, sample workflows and staffing models for deployment.

Key Market Segments Evaluated

By Diagnostic Method

Blood-based biomarker tests
CSF biomarker tests
PET imaging
Genetic testing

By Biomarker Target

Amyloid pathology
Tau pathology
Neurodegeneration and neuroinflammation
Genetic risk

By End User

Hospitals and memory clinics
Reference and diagnostic laboratories
Imaging centers
Pharmaceutical and research institutions

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Denmark
- Finland
- Netherlands
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Taiwan
- Indonesia
- Vietnam
- Australia
- Philippines
- Malaysia
- Rest of APAC
Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Israel
- Turkey
- Nigeria
- South Africa
- Rest of MEA
Latin America
- Brazil
- Argentina
- Chile
- Colombia
- Rest of LATAM

Conclusion & Recommendations

The outlook is strongly positive. Revenue rises from USD 1.19 Billion in 2026 to USD 4.05 Billion in 2035 as blood tests become routine and PET imaging stabilizes as the confirmatory standard. Regulatory clearances and payer coverage are converting clinical evidence into volume, and Asia-Pacific supplies the fastest incremental growth over the period.

What Strategic Positioning Recommendations Does NMSC Offer?

NMSC recommends that vendors prioritize cleared kits on widely installed analyzers, secure reimbursement codes early and invest in multi biomarker algorithms that reduce indeterminate results. Laboratory networks should pair branded panels with physician education, while radiotracer companies should defend therapy selection labels and add tau imaging to complete diagnostic portfolios.

What Is the Investment Attractiveness of the Market?

Investment attractiveness is high but selective. Growth above 14% a year, recurring reagent revenue and strong regulatory barriers favor leading participants. Valuation risk arises from reimbursement uncertainty and competition from laboratory developed tests. Capital is best directed to companies with cleared assays, scalable manufacturing and partnerships with drug developers or national laboratory networks.

What Are the Market Shifts and Key Risks?

Shifts include movement from specialist to primary care testing, adoption of dual cutoff interpretation and wider use of tau markers. Risks include uneven coverage, false results affecting patient trust, workforce shortages in memory clinics and price erosion once multiple cleared tests compete. Companies should monitor guideline updates because they can quickly change eligible populations.

What Are the Primary Growth Pathways Through 2035?

Growth pathways include rule out testing in primary care, expansion into Asia-Pacific and Middle East memory clinics, companion testing for therapies and longitudinal monitoring. Multi biomarker panels and automation extend existing instruments into new indications. Combined, these pathways support the forecast increase of USD 2.86 Billion between 2026 and 2035.

FAQs

Sources & References

Alzheimer’s Association, 2026 Alzheimer’s Disease Facts and Figures

alz.org/facts

World Health Organization, Dementia

who.int

U.S. Food and Drug Administration, FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease (May 16, 2025)

fda.gov

Quanterix Corporation, Form 10-Q for the period ended June 30, 2026

sec.gov

Quanterix Corporation, Form 8-K second quarter 2026 results

sec.gov

Lantheus Holdings, Inc., Form 10-Q for the period ended June 30, 2026

sec.gov

Lantheus Holdings, Inc., Form 10-K for the year ended December 31, 2025

sec.gov

Beckman Coulter Diagnostics, FDA Breakthrough Device Designation press release (January 28, 2025)

beckmancoulter.com

Quest Diagnostics, news release on Elecsys pTau217 and AD-Detect (August 24, 2026)

s2.q4cdn.com

About the Author

Mayurima Roy

Mayurima Roy is Research Analyst at Next Move Strategy Consulting, where she has spent 4 years working across the firm's full industry coverage rather than a single fixed vertical. Her work centers on structured research, ongoing trend tracking, competitive assessment, and insight-led content development, translating complex market data into clear, decision-ready narratives that support informed client decision-making across diverse global industries, market sectors, and world regions every day.

About the Reviewer

Supradip Baul

Supradip Baul is an accomplished business consultant and strategist with over a decade of rich experience in market intelligence, strategy, technology, and business transformation. His work has included rigorous qualitative and quantitative analysis across multiple industries, helping clients shape investment decisions and long-term roadmaps. Earlier in his career, he was associated with Gartner, where he contributed to industry-leading reports and market share analyses. He has worked with leading global companies and holds an MBA with a dual specialization in Marketing and Finance.

Download Free Sample

Full Name *

Business Email Id *

Country Code *

Phone Number *

Message

Yes, I have read the Privacy Policy

Testimonials

View All Testimonials

HENRI KNYPHAUSEN

Partner at Singulier [Ex-BCG]

I recently engaged NEXTMSC.com for a commercial due diligence project within the intralogistics sector, and I am pleased to provide a reference based on my experience. In utilizing NEXTMSC.com's services, I found their report to offer valuable insights into market dynamics and key industry players. The initial report provided a solid foundation for our analysis. However, as we were investigating a smaller target in the market, and I had specific customization requests requiring additional research. These requests included detailed information on product portfolios of various players and sub-market sizes, both inclusive and exclusive of certain product categories. NEXTMSC.com demonstrated commendable responsiveness and agility in accommodating these customization requests. Within a timeframe of 1-2 weeks, they delivered a revised report that met our specific needs. Furthermore, they were receptive to my follow-up inquiries, ensuring clarity and understanding of the data provided. The final deliverable significantly contributed to our due diligence efforts. One of NEXTMSC.com's notable strengths lies in their qualitative research capabilities. However, for future engagements, I would recommend the inclusion of a quantified market model in Excel format. Such a model would offer the ability to conduct in-depth analyses and explore various market segments, including country-specific data and subcomponent breakdowns. Based on my positive experience, I would not hesitate to work with NEXTMSC.com again. Their responsiveness, willingness to accommodate customization requests, and commitment to delivering actionable insights make them a reliable partner for commercial research projects.

ROSS J MCKENZIE

Business Insight Manager

“Next MSC have been incredibly helpful in providing detailed & robust information on our market, alongside quantifying growth by different segments. The process to procure was simple and easy, with sample reports and regular contact to ensure we had what we needed. Succinct detail on their sources & methodologies is also greatly received, allowing transparency in this respect helps build trust in the detail you pay for. Joseph in particular was fantastic, and helped ensure efficient provision of the insight pack – thank you NMSC!”.

PRATYUSH KUMAR DAS

Assistant Manager

We would like to express our appreciation for the data and insights provided by nextmsc. We are very pleased with the quality and depth of the information, which has proven to be highly valuable and beneficial for our business decision-making.

GAURAV JAISWAL

Founder & CEO

The EV Charging market research report provided by the NextMSC was exceptionally detailed and insightful. It offered a comprehensive analysis that proved to be a game-changer for our strategic planning. Truly a testament to the NextMSC’s expertise and thoroughness in EV market landscape & analysis.

SEMIH KAVAKLIOGLU

Co-Founder & Sales Manager

I work a lot in the marketing industry and I know that research is an essential part of any campaign. I have used Market research reports for my own products and I found them to be very informative and well-researched. The team here produces insightful reports for a good price

Alzheimer’s disease diagnostics Market Analysis and Forecast (2026–2035)

Select License

Research Methodology

Qualitative Approach

Our Specialized Toolbox for Industry-Specific Market Research

Information Procurement

Market Research Approach

Porters Five Forces Analysis

SWOT Analysis

Forecasting

What Is the Alzheimer’s Disease Diagnostics Market Size?

Alzheimer’s disease diagnostics Market Analysis and Forecast Revenue Forecast

Key Takeaways

Ecosystem Analysis of the Alzheimer’s Disease Diagnostics Market

What Does the Alzheimer’s Disease Diagnostics Market Encompass?

Key Emerging Trends

How Are Blood Biomarker Tests Reshaping Diagnostic Pathways?

Why Are Multi Biomarker Panels Gaining Traction?

How Is Laboratory Automation Extending Testing Beyond Specialist Centers?

How Is PET Imaging Adapting to Therapy Selection?

Market Drivers & Dynamics

Growth Drivers

What Is the Primary Growth Driver?

How Is Regulatory and Payer Progress Driving Market Growth?

Growth Inhibitors

What Is Restraining the Market?

Segmentation Analysis

Which Diagnostic Method Leads the Market and Which Grows Fastest?

Growth Opportunities

Can Primary Care Rule Out Testing Unlock New Volume?

Will Emerging Markets Create the Next Wave of Demand?

How Can Pharmaceutical Partnerships Create Recurring Revenue?

Regional Outlook

North America Alzheimer’s Disease Diagnostics Market

Key National Markets

Europe Alzheimer’s Disease Diagnostics Market

Key National Markets

Asia-Pacific Alzheimer’s Disease Diagnostics Market

Key National Markets

Middle East & Africa Alzheimer’s Disease Diagnostics Market

Key National Markets

Latin America Alzheimer’s Disease Diagnostics Market

Key National Markets

Strategic Framework of the Alzheimer’s Disease Diagnostics Market

Competitive Landscape

How Do Companies Compete in This Market?

Which Company Archetypes Dominate?

How Are Companies Differentiating Through Innovation?

What Is the Level of M&A Activity?

Key Market Players

Latest Developments

Expert Insights

Maria C. Carrillo

Analyst Interpretation

Market Interpretation

Investment Opportunities

Where Are Capital Inflows Concentrated?

How Does Infrastructure Investment Shape Returns?

What Are the ESG Considerations?

Key Benefits for Stakeholders

How Does the Report Help Enterprise and Industry Leaders?

How Does the Report Help Investors and Financial Analysts?

How Does the Report Help Technology Vendors and Clinical Teams?

Key Market Segments Evaluated

By Diagnostic Method

By Biomarker Target

By End User

By Region

Conclusion & Recommendations

What Strategic Positioning Recommendations Does NMSC Offer?

What Is the Investment Attractiveness of the Market?

What Are the Market Shifts and Key Risks?

What Are the Primary Growth Pathways Through 2035?

FAQs

Sources & References

About the Author

About the Reviewer

Download Free Sample

Testimonials

HENRI KNYPHAUSEN